JP2003535017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003535017A5 JP2003535017A5 JP2000556800A JP2000556800A JP2003535017A5 JP 2003535017 A5 JP2003535017 A5 JP 2003535017A5 JP 2000556800 A JP2000556800 A JP 2000556800A JP 2000556800 A JP2000556800 A JP 2000556800A JP 2003535017 A5 JP2003535017 A5 JP 2003535017A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- particles
- powder
- microparticles
- dispersion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 262
- 239000003795 chemical substances by application Substances 0.000 description 193
- 239000002245 particle Substances 0.000 description 178
- 239000000843 powder Substances 0.000 description 162
- 239000006185 dispersion Substances 0.000 description 142
- 239000000427 antigen Substances 0.000 description 115
- 102000038129 antigens Human genes 0.000 description 115
- 108091007172 antigens Proteins 0.000 description 115
- 230000000975 bioactive Effects 0.000 description 108
- 239000011859 microparticle Substances 0.000 description 99
- 241000700605 Viruses Species 0.000 description 96
- 239000002609 media Substances 0.000 description 93
- 210000004027 cells Anatomy 0.000 description 87
- 238000009472 formulation Methods 0.000 description 86
- 239000004094 surface-active agent Substances 0.000 description 73
- 238000000034 method Methods 0.000 description 66
- 230000004044 response Effects 0.000 description 66
- 230000028993 immune response Effects 0.000 description 61
- 150000001875 compounds Chemical class 0.000 description 58
- 239000000725 suspension Substances 0.000 description 50
- 102000004169 proteins and genes Human genes 0.000 description 48
- 108090000623 proteins and genes Proteins 0.000 description 48
- 239000004604 Blowing Agent Substances 0.000 description 47
- 230000000694 effects Effects 0.000 description 46
- 239000007921 spray Substances 0.000 description 46
- 239000000839 emulsion Substances 0.000 description 45
- WTWWXOGTJWMJHI-UHFFFAOYSA-N Perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 44
- 239000007788 liquid Substances 0.000 description 42
- 230000002708 enhancing Effects 0.000 description 41
- 229960001217 perflubron Drugs 0.000 description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- 101700038759 VP1 Proteins 0.000 description 38
- 238000004519 manufacturing process Methods 0.000 description 38
- 238000001694 spray drying Methods 0.000 description 38
- 229960005486 vaccines Drugs 0.000 description 38
- 102000004851 Immunoglobulin G Human genes 0.000 description 37
- 108090001095 Immunoglobulin G Proteins 0.000 description 37
- 101710043164 Segment-4 Proteins 0.000 description 37
- 101700005460 hemA Proteins 0.000 description 37
- 239000000185 hemagglutinin Substances 0.000 description 37
- 102000004965 antibodies Human genes 0.000 description 36
- 108090001123 antibodies Proteins 0.000 description 36
- 239000003814 drug Substances 0.000 description 36
- 239000000463 material Substances 0.000 description 36
- 239000011780 sodium chloride Substances 0.000 description 34
- 102000004196 processed proteins & peptides Human genes 0.000 description 33
- 108090000765 processed proteins & peptides Proteins 0.000 description 33
- 229940079593 drugs Drugs 0.000 description 32
- 230000036039 immunity Effects 0.000 description 31
- 230000001717 pathogenic Effects 0.000 description 31
- 210000004072 Lung Anatomy 0.000 description 30
- 150000003904 phospholipids Chemical class 0.000 description 30
- -1 amine salts Chemical class 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
- 239000000443 aerosol Substances 0.000 description 25
- 239000006199 nebulizer Substances 0.000 description 24
- 238000009835 boiling Methods 0.000 description 23
- 239000003380 propellant Substances 0.000 description 23
- 230000002068 genetic Effects 0.000 description 22
- 230000003053 immunization Effects 0.000 description 22
- 238000002649 immunization Methods 0.000 description 21
- 239000011159 matrix material Substances 0.000 description 21
- 244000052769 pathogens Species 0.000 description 21
- NBVXSUQYWXRMNV-UHFFFAOYSA-N Fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 19
- 230000001965 increased Effects 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000005755 formation reaction Methods 0.000 description 18
- 210000001744 T-Lymphocytes Anatomy 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- 150000002430 hydrocarbons Chemical class 0.000 description 16
- 230000000051 modifying Effects 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 210000003800 Pharynx Anatomy 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 15
- 239000003623 enhancer Substances 0.000 description 15
- 230000003612 virological Effects 0.000 description 15
- 102000018358 Immunoglobulins Human genes 0.000 description 14
- 108060003951 Immunoglobulins Proteins 0.000 description 14
- 229940067631 Phospholipids Drugs 0.000 description 14
- 239000002671 adjuvant Substances 0.000 description 14
- 230000000240 adjuvant Effects 0.000 description 14
- 230000002776 aggregation Effects 0.000 description 14
- 150000001720 carbohydrates Chemical class 0.000 description 14
- 235000014633 carbohydrates Nutrition 0.000 description 14
- 230000000875 corresponding Effects 0.000 description 14
- 239000007789 gas Substances 0.000 description 14
- 244000005700 microbiome Species 0.000 description 14
- 238000002156 mixing Methods 0.000 description 14
- 230000002829 reduced Effects 0.000 description 14
- 241000712461 unidentified influenza virus Species 0.000 description 14
- 238000004220 aggregation Methods 0.000 description 13
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 13
- 230000001939 inductive effect Effects 0.000 description 13
- 238000002664 inhalation therapy Methods 0.000 description 13
- 238000011081 inoculation Methods 0.000 description 13
- 239000004005 microsphere Substances 0.000 description 13
- 239000011148 porous material Substances 0.000 description 13
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 239000012527 feed solution Substances 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 239000007900 aqueous suspension Substances 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 230000001976 improved Effects 0.000 description 11
- 230000002685 pulmonary Effects 0.000 description 11
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 10
- 210000004400 Mucous Membrane Anatomy 0.000 description 10
- 210000002966 Serum Anatomy 0.000 description 10
- 238000004166 bioassay Methods 0.000 description 10
- 239000000969 carrier Substances 0.000 description 10
- 201000009910 diseases by infectious agent Diseases 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 241001430294 unidentified retrovirus Species 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 229940112141 Dry Powder Inhaler Drugs 0.000 description 9
- 210000000987 Immune System Anatomy 0.000 description 9
- 241001500351 Influenzavirus A Species 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 239000003599 detergent Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 206010003816 Autoimmune disease Diseases 0.000 description 7
- 239000004215 Carbon black (E152) Substances 0.000 description 7
- KILNVBDSWZSGLL-KXQOOQHDSA-N Dipalmitoylphosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 7
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 230000000692 anti-sense Effects 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 7
- 230000003308 immunostimulating Effects 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- 238000011068 load Methods 0.000 description 7
- 230000001404 mediated Effects 0.000 description 7
- 231100000486 side effect Toxicity 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 230000001839 systemic circulation Effects 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000036912 Bioavailability Effects 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102000004388 Interleukin-4 Human genes 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- 229940071648 Metered Dose Inhaler Drugs 0.000 description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000035514 bioavailability Effects 0.000 description 6
- 229920001400 block copolymer Polymers 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 230000004059 degradation Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 150000002170 ethers Chemical class 0.000 description 6
- 238000005189 flocculation Methods 0.000 description 6
- 230000016615 flocculation Effects 0.000 description 6
- 150000002222 fluorine compounds Chemical class 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 230000003834 intracellular Effects 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000000699 topical Effects 0.000 description 6
- 210000004881 tumor cells Anatomy 0.000 description 6
- 102100020197 CFP Human genes 0.000 description 5
- 210000004443 Dendritic Cells Anatomy 0.000 description 5
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 5
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 5
- 210000004698 Lymphocytes Anatomy 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000002238 attenuated Effects 0.000 description 5
- 230000001413 cellular Effects 0.000 description 5
- 108091006028 chimera Proteins 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037240 fusion proteins Human genes 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 229940050526 hydroxyethylstarch Drugs 0.000 description 5
- 239000002955 immunomodulating agent Substances 0.000 description 5
- 230000002584 immunomodulator Effects 0.000 description 5
- 229940121354 immunomodulators Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002458 infectious Effects 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000000717 retained Effects 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 238000000638 solvent extraction Methods 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-Tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 4
- 210000003719 B-Lymphocytes Anatomy 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 208000006454 Hepatitis Diseases 0.000 description 4
- 210000000088 Lip Anatomy 0.000 description 4
- 210000001331 Nose Anatomy 0.000 description 4
- 210000002381 Plasma Anatomy 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 4
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 4
- TXEYQDLBPFQVAA-UHFFFAOYSA-N Tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 4
- DLENCXDZIZEKQI-KINGROEASA-N Texas Red DHPE Chemical compound CCN(CC)CC.[O-]S(=O)(=O)C1=CC(S(=O)(=O)NCCOP(O)(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 DLENCXDZIZEKQI-KINGROEASA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 239000008365 aqueous carrier Substances 0.000 description 4
- 238000000889 atomisation Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 150000004676 glycans Polymers 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000002563 ionic surfactant Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000000670 limiting Effects 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229950011087 perflunafene Drugs 0.000 description 4
- UWEYRJFJVCLAGH-UHFFFAOYSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C21F UWEYRJFJVCLAGH-UHFFFAOYSA-N 0.000 description 4
- 239000002831 pharmacologic agent Substances 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 229920001993 poloxamer 188 Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 150000004804 polysaccharides Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000005057 refrigeration Methods 0.000 description 4
- 230000000241 respiratory Effects 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- CUCAXMCEXWMQTL-UHFFFAOYSA-N 1-bromo-1-fluoroheptane Chemical compound CCCCCCC(F)Br CUCAXMCEXWMQTL-UHFFFAOYSA-N 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl dihydrogen phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 3
- BLEMLGBVQSNDOD-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CN=C2[C]1C(Cl)=C(Br)C=C2 BLEMLGBVQSNDOD-AEOCFKNESA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 3
- 229960000846 Camphor Drugs 0.000 description 3
- 229940107161 Cholesterol Drugs 0.000 description 3
- 241000723346 Cinnamomum camphora Species 0.000 description 3
- 206010012601 Diabetes mellitus Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010022000 Influenza Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 229920002521 Macromolecule Polymers 0.000 description 3
- 210000000214 Mouth Anatomy 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N Perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 3
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 3
- 230000035493 absolute bioavailability Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000890 antigenic Effects 0.000 description 3
- 125000004429 atoms Chemical group 0.000 description 3
- 230000001580 bacterial Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000003124 biologic agent Substances 0.000 description 3
- 239000004067 bulking agent Substances 0.000 description 3
- 229930007890 camphor Natural products 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 102000009410 chemokine receptors Human genes 0.000 description 3
- 108050000299 chemokine receptors Proteins 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 3
- LKYXEULZVGJVTG-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH] LKYXEULZVGJVTG-UHFFFAOYSA-N 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 230000000534 elicitor Effects 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 108010074605 gamma-Globulins Proteins 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000002209 hydrophobic Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000002934 lysing Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 108010045030 monoclonal antibodies Proteins 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000021313 oleic acid Nutrition 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 244000045947 parasites Species 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 230000001177 retroviral Effects 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 230000001131 transforming Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-Heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(Z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 2
- YKIOPDIXYAUOFN-UHFFFAOYSA-N 2,3-di(icosanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC YKIOPDIXYAUOFN-UHFFFAOYSA-N 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- PRKQVKDSMLBJBJ-UHFFFAOYSA-N Ammonium carbonate Chemical compound N.N.OC(O)=O PRKQVKDSMLBJBJ-UHFFFAOYSA-N 0.000 description 2
- 125000006414 CCl Chemical group ClC* 0.000 description 2
- 102100011842 CEACAM5 Human genes 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- DJHJJVWPFGHIPH-OODMECLYSA-N Chitin Chemical compound O[C@@H]1C(NC(=O)C)[C@H](O)OC(CO)[C@H]1COC[C@H]1C(NC(C)=O)[C@@H](O)[C@H](COC[C@H]2C([C@@H](O)[C@H](O)C(CO)O2)NC(C)=O)C(CO)O1 DJHJJVWPFGHIPH-OODMECLYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108060003023 F Proteins 0.000 description 2
- 101700010580 FLO11 Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 208000006572 Human Influenza Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229940047124 Interferons Drugs 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000000585 Interleukin-9 Human genes 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 229920000126 Latex Polymers 0.000 description 2
- 229940115931 Listeria monocytogenes Drugs 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 210000004324 Lymphatic System Anatomy 0.000 description 2
- 210000003563 Lymphoid Tissue Anatomy 0.000 description 2
- 102100006037 MUC1 Human genes 0.000 description 2
- 101700052761 MUC1 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 210000004379 Membranes Anatomy 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 210000003928 Nasal Cavity Anatomy 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 102100017349 PTPRN Human genes 0.000 description 2
- 101700074964 PTPRN Proteins 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 229920001774 Perfluoroether Polymers 0.000 description 2
- 229940044519 Poloxamer 188 Drugs 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 239000004721 Polyphenylene oxide Chemical class 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 102000014961 Protein Precursors Human genes 0.000 description 2
- 108010078762 Protein Precursors Proteins 0.000 description 2
- 210000003660 Reticulum Anatomy 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101710023234 Segment 5 Proteins 0.000 description 2
- 230000037165 Serum Concentration Effects 0.000 description 2
- 210000000952 Spleen Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 102100009534 TNF Human genes 0.000 description 2
- 210000000447 Th1 Cells Anatomy 0.000 description 2
- 210000004241 Th2 Cells Anatomy 0.000 description 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
- 108070000030 Viral receptors Proteins 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 231100000494 adverse effect Toxicity 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 235000012501 ammonium carbonate Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004164 analytical calibration Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 2
- 230000003385 bacteriostatic Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229960000074 biopharmaceuticals Drugs 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atoms Chemical group C* 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000005465 channeling Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000139 costimulatory Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 239000002612 dispersion media Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000001747 exhibiting Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002519 immonomodulatory Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 230000003116 impacting Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003071 memory T lymphocyte Anatomy 0.000 description 2
- 230000000813 microbial Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002357 osmotic agent Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 229960004624 perflexane Drugs 0.000 description 2
- UIOCPFVEDHPJES-UHFFFAOYSA-N perfluoro-4-methylquinolizidine Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(C(F)(F)F)(F)N21 UIOCPFVEDHPJES-UHFFFAOYSA-N 0.000 description 2
- QKENRHXGDUPTEM-UHFFFAOYSA-N perfluorophenanthrene Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C3(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C3(F)C(F)(F)C(F)(F)C21F QKENRHXGDUPTEM-UHFFFAOYSA-N 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920000570 polyether Chemical class 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000000087 stabilizing Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000004936 stimulating Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 230000001052 transient Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 239000004034 viscosity adjusting agent Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol;(Z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OFBLZCXWVROESG-PKPIPKONSA-N (2S)-1,2,3-trihydroxyheptan-4-one Chemical compound CCCC(=O)C(O)[C@@H](O)CO OFBLZCXWVROESG-PKPIPKONSA-N 0.000 description 1
- KBHBUUBXEQUIMV-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluorooctane Chemical compound FC(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F KBHBUUBXEQUIMV-UHFFFAOYSA-N 0.000 description 1
- LWRNQOBXRHWPGE-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8a-heptadecafluoro-8-(trifluoromethyl)naphthalene Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(C(F)(F)F)(F)C(F)(F)C(F)(F)C(F)(F)C21F LWRNQOBXRHWPGE-UHFFFAOYSA-N 0.000 description 1
- IJSYUQGQBMIFCS-UHFFFAOYSA-N 1,1,2,2,3,3,4,4-octafluoro-5,5,6,6-tetrakis(trifluoromethyl)cyclohexane Chemical compound FC(F)(F)C1(C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(C(F)(F)F)C(F)(F)F IJSYUQGQBMIFCS-UHFFFAOYSA-N 0.000 description 1
- WXGNWUVNYMJENI-UHFFFAOYSA-N 1,1,2,2-tetrafluoroethane Chemical compound FC(F)C(F)F WXGNWUVNYMJENI-UHFFFAOYSA-N 0.000 description 1
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-Difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 1
- OUAZVZXMMWFQQA-UHFFFAOYSA-N 1,1-dichloro-1-fluorooctane Chemical compound CCCCCCCC(F)(Cl)Cl OUAZVZXMMWFQQA-UHFFFAOYSA-N 0.000 description 1
- OQYNFBPKTVQOKO-UHFFFAOYSA-N 1,1-dichlorooctane Chemical compound CCCCCCCC(Cl)Cl OQYNFBPKTVQOKO-UHFFFAOYSA-N 0.000 description 1
- ZAKBPRIDLSBYQQ-VHSXEESVSA-N 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical class CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OC[C@@H](O)CO ZAKBPRIDLSBYQQ-VHSXEESVSA-N 0.000 description 1
- IJFVSSZAOYLHEE-SSEXGKCCSA-O 1,2-dilauroyl-sn-glycero-3-phosphocholine(1+) Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-O 0.000 description 1
- TWRZCCMKTIMFOF-UHFFFAOYSA-N 1,4-dibromo-1-fluorobutane Chemical compound FC(Br)CCCBr TWRZCCMKTIMFOF-UHFFFAOYSA-N 0.000 description 1
- AZWWGJSTRKPCNY-UHFFFAOYSA-N 1,4-dichloro-1-fluorobutane Chemical compound FC(Cl)CCCCl AZWWGJSTRKPCNY-UHFFFAOYSA-N 0.000 description 1
- GANWURNTAWQJOQ-UHFFFAOYSA-N 1,6-dibromo-1-fluorohexane Chemical compound FC(Br)CCCCCBr GANWURNTAWQJOQ-UHFFFAOYSA-N 0.000 description 1
- ALAJQWDRPFKABH-UHFFFAOYSA-N 1,6-dichloro-1-fluorohexane Chemical compound FC(Cl)CCCCCCl ALAJQWDRPFKABH-UHFFFAOYSA-N 0.000 description 1
- VZSHMLFEJCRGQU-UHFFFAOYSA-N 1,8-dichloro-1-fluorooctane Chemical compound FC(Cl)CCCCCCCCl VZSHMLFEJCRGQU-UHFFFAOYSA-N 0.000 description 1
- RNYLKZQSBSAUNR-UHFFFAOYSA-N 1-bromo-1-fluorobutane Chemical compound CCCC(F)Br RNYLKZQSBSAUNR-UHFFFAOYSA-N 0.000 description 1
- WJNMVKYLIUVQPI-UHFFFAOYSA-N 1-bromo-1-fluorohexane Chemical compound CCCCCC(F)Br WJNMVKYLIUVQPI-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- SYVYTZLRTMPUCD-UHFFFAOYSA-N 1-chloro-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Cl SYVYTZLRTMPUCD-UHFFFAOYSA-N 0.000 description 1
- OFERIJCSHDJMSA-UHFFFAOYSA-N 1-fluorohexane Chemical compound CCCCCCF OFERIJCSHDJMSA-UHFFFAOYSA-N 0.000 description 1
- JRHNUZCXXOTJCA-UHFFFAOYSA-N 1-fluoropropane Chemical compound CCCF JRHNUZCXXOTJCA-UHFFFAOYSA-N 0.000 description 1
- OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-Dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 1
- CYXIKYKBLDZZNW-UHFFFAOYSA-N 2-Chloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)CCl CYXIKYKBLDZZNW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- VHOQXEIFYTTXJU-UHFFFAOYSA-N 2-methylbuta-1,3-diene;2-methylprop-1-ene Chemical compound CC(C)=C.CC(=C)C=C VHOQXEIFYTTXJU-UHFFFAOYSA-N 0.000 description 1
- ROGIWVXWXZRRMZ-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1 ROGIWVXWXZRRMZ-UHFFFAOYSA-N 0.000 description 1
- KUDUQBURMYMBIJ-UHFFFAOYSA-N 2-prop-2-enoyloxyethyl prop-2-enoate Chemical compound C=CC(=O)OCCOC(=O)C=C KUDUQBURMYMBIJ-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UMZBRFQRSA-N 4-[(3R,5S,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CCC1(C)C1C2C2CCC(C(CCC(O)=O)C)C2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-UMZBRFQRSA-N 0.000 description 1
- JDCCCHBBXRQRGU-UHFFFAOYSA-N 5-phenylpenta-2,4-dienenitrile Chemical compound N#CC=CC=CC1=CC=CC=C1 JDCCCHBBXRQRGU-UHFFFAOYSA-N 0.000 description 1
- 102100008450 AFP Human genes 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 101710002767 BACOVA_02645 Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 229940093761 Bile Salts Drugs 0.000 description 1
- 229910014264 BrF Inorganic materials 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N Butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 102100019487 CCL11 Human genes 0.000 description 1
- 102100019494 CCL17 Human genes 0.000 description 1
- 101700084100 CCL17 Proteins 0.000 description 1
- 102100019492 CCL19 Human genes 0.000 description 1
- 101700049349 CCL19 Proteins 0.000 description 1
- 102100012031 CCL21 Human genes 0.000 description 1
- 101700070431 CCL21 Proteins 0.000 description 1
- 102100012030 CCL24 Human genes 0.000 description 1
- 102100016449 CCL5 Human genes 0.000 description 1
- 101700070842 CCR3 Proteins 0.000 description 1
- 102100005861 CCR3 Human genes 0.000 description 1
- 102000004498 CCR4 Receptors Human genes 0.000 description 1
- 108010017317 CCR4 Receptors Proteins 0.000 description 1
- 101700043583 CCR5 Proteins 0.000 description 1
- 102100012080 CCR5 Human genes 0.000 description 1
- 102000004274 CCR5 Receptors Human genes 0.000 description 1
- 108010017088 CCR5 Receptors Proteins 0.000 description 1
- 102100008151 CCR7 Human genes 0.000 description 1
- ARQRPTNYUOLOGH-UHFFFAOYSA-N CHCl3 Chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 description 1
- 102100002226 CXCR3 Human genes 0.000 description 1
- 101700079756 CXCR3 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102000004040 Capsid Proteins Human genes 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 108010082548 Chemokine CCL11 Proteins 0.000 description 1
- 108010083647 Chemokine CCL24 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
- YACLQRRMGMJLJV-UHFFFAOYSA-N Chloroprene Chemical compound ClC(=C)C=C YACLQRRMGMJLJV-UHFFFAOYSA-N 0.000 description 1
- 229910020313 ClF Inorganic materials 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 229940097362 Cyclodextrins Drugs 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- AZSZCFSOHXEJQE-UHFFFAOYSA-N Dibromodifluoromethane Chemical compound FC(F)(Br)Br AZSZCFSOHXEJQE-UHFFFAOYSA-N 0.000 description 1
- 108020004530 EC 2.2.1.2 Proteins 0.000 description 1
- 102000033180 ERVK-6 Human genes 0.000 description 1
- 101710038044 ERVK-6 Proteins 0.000 description 1
- 101710027967 ERVW-1 Proteins 0.000 description 1
- 210000000613 Ear Canal Anatomy 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N Ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101700014779 GLB1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010018075 Generalised anxiety disease Diseases 0.000 description 1
- 102000008214 Glutamate decarboxylases Human genes 0.000 description 1
- 108091022086 Glutamate decarboxylases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N Glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 102100020459 HLA-B Human genes 0.000 description 1
- 101710009008 HLA-B Proteins 0.000 description 1
- 229920002456 HOTAIR Polymers 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 241000712887 Hantaan virus Lee Species 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000007514 Herpes Zoster Diseases 0.000 description 1
- WMIYKQLTONQJES-UHFFFAOYSA-N Hexafluoroethane Chemical compound FC(F)(F)C(F)(F)F WMIYKQLTONQJES-UHFFFAOYSA-N 0.000 description 1
- 102000005657 Human Immunodeficiency Virus nef Gene Products Human genes 0.000 description 1
- 108010084873 Human Immunodeficiency Virus nef Gene Products Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108090001122 Immunoglobulin A Proteins 0.000 description 1
- 108090001124 Immunoglobulin E Proteins 0.000 description 1
- 108090001096 Immunoglobulin M Proteins 0.000 description 1
- 102000004551 Interleukin-10 Receptors Human genes 0.000 description 1
- 108010017550 Interleukin-10 Receptors Proteins 0.000 description 1
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 1
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 description 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000010682 Interleukin-9 Receptors Human genes 0.000 description 1
- 108010038414 Interleukin-9 Receptors Proteins 0.000 description 1
- 229940065638 Intron A Drugs 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 206010025135 Lupus erythematosus Diseases 0.000 description 1
- 210000002751 Lymph Anatomy 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 229960003035 MAGNESIUM GLUCONATE Drugs 0.000 description 1
- 101700036258 MECOM Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- CTUVIUYTHWPELF-IYEMJOQQSA-L Magnesium gluconate Chemical compound [Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CTUVIUYTHWPELF-IYEMJOQQSA-L 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N Mannan Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N Methadone Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- 229940051875 Mucins Drugs 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000015528 Myelin Basic Protein Human genes 0.000 description 1
- 108010025255 Myelin Basic Protein Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- LKQLRGMMMAHREN-YJFXYUILSA-N N-stearoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC LKQLRGMMMAHREN-YJFXYUILSA-N 0.000 description 1
- 101700062818 NP Proteins 0.000 description 1
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 229940052778 Neisseria meningitidis Drugs 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- 229960003753 Nitric Oxide Drugs 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- GVGCUCJTUSOZKP-UHFFFAOYSA-N Nitrogen trifluoride Chemical class FN(F)F GVGCUCJTUSOZKP-UHFFFAOYSA-N 0.000 description 1
- 101710003000 ORF1/ORF2 Proteins 0.000 description 1
- 230000035536 Oral bioavailability Effects 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- UJMWVICAENGCRF-UHFFFAOYSA-N Oxygen difluoride Chemical class FOF UJMWVICAENGCRF-UHFFFAOYSA-N 0.000 description 1
- 101710043203 P23p89 Proteins 0.000 description 1
- 102100018130 PRLR Human genes 0.000 description 1
- 102100016187 PVR Human genes 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- RVZRBWKZFJCCIB-UHFFFAOYSA-N Perfluorotributylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RVZRBWKZFJCCIB-UHFFFAOYSA-N 0.000 description 1
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000003200 Peritoneal Cavity Anatomy 0.000 description 1
- 229960000502 Poloxamer Drugs 0.000 description 1
- 229920002517 Poloxamer 338 Polymers 0.000 description 1
- 229940044476 Poloxamer 407 Drugs 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940098458 Powder Spray Drugs 0.000 description 1
- 108010002519 Prolactin Receptors Proteins 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N Raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 210000001533 Respiratory Mucosa Anatomy 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 101710024753 SERPINB14 Proteins 0.000 description 1
- 229960005055 SODIUM ASCORBATE Drugs 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- UPMFZISCCZSDND-JJKGCWMISA-M Sodium gluconate Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O UPMFZISCCZSDND-JJKGCWMISA-M 0.000 description 1
- 229940005574 Sodium gluconate Drugs 0.000 description 1
- 229960005078 Sorbitan sesquioleate Drugs 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 229960000391 Sorbitan trioleate Drugs 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229940076185 Staphylococcus aureus Drugs 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920000978 Start codon Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 229940031000 Streptococcus pneumoniae Drugs 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 239000002174 Styrene-butadiene Substances 0.000 description 1
- 230000035737 Systemic bioavailability Effects 0.000 description 1
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 1
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 description 1
- 102100008098 TALDO1 Human genes 0.000 description 1
- 102100019730 TP53 Human genes 0.000 description 1
- 101710026335 TP53 Proteins 0.000 description 1
- 229940073585 TROMETHAMINE HYDROCHLORIDE Drugs 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 206010043521 Throat irritation Diseases 0.000 description 1
- 230000035852 Tmax Effects 0.000 description 1
- 230000037253 Total clearance Effects 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 210000003708 Urethra Anatomy 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 101710027952 VEPH1 Proteins 0.000 description 1
- 101700055524 VME1 Proteins 0.000 description 1
- 101700028070 VPX Proteins 0.000 description 1
- 210000001215 Vagina Anatomy 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 229940118696 Vibrio cholerae Drugs 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108090000834 Viral Antibodies Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 102000016350 Viral Proteins Human genes 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N Xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 Xylazine Drugs 0.000 description 1
- 229940118695 Yersinia pestis Drugs 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 244000150668 Zea mays subsp mays Species 0.000 description 1
- URRBLVUOXIGNQR-HXUWFJFHSA-N [(1R)-1-phenylethyl] N-(2-aminoethyl)-N-[(3-methoxy-4-phenylmethoxyphenyl)methyl]carbamate Chemical compound C1([C@@H](C)OC(=O)N(CCN)CC=2C=C(C(=CC=2)OCC=2C=CC=CC=2)OC)=CC=CC=C1 URRBLVUOXIGNQR-HXUWFJFHSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- SNKAWJBJQDLSFF-YEUCEMRASA-N [2-({2,3-bis[(9Z)-octadec-9-enoyloxy]propyl phosphonato}oxy)ethyl]trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-YEUCEMRASA-N 0.000 description 1
- PRXRUNOAOLTIEF-XDTJCZEISA-N [2-[(2R,3S,4R)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-XDTJCZEISA-N 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940059913 ammonium carbonate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229960001040 ammonium chloride Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000181 anti-adherence Effects 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- NTXGQCSETZTARF-UHFFFAOYSA-N buta-1,3-diene;prop-2-enenitrile Chemical compound C=CC=C.C=CC#N NTXGQCSETZTARF-UHFFFAOYSA-N 0.000 description 1
- DFFDSQBEGQFJJU-UHFFFAOYSA-M butyl carbonate Chemical compound CCCCOC([O-])=O DFFDSQBEGQFJJU-UHFFFAOYSA-M 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003850 cellular structures Anatomy 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 150000001805 chlorine compounds Chemical group 0.000 description 1
- 229920005556 chlorobutyl Polymers 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002153 concerted Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical compound CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000003413 degradative Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- NFLWUMRGJYTJIN-PNIOQBSNSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-PNIOQBSNSA-N 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002222 downregulating Effects 0.000 description 1
- 101710019483 ebgA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 210000003162 effector T lymphocyte Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 230000003628 erosive Effects 0.000 description 1
- CGPRUXZTHGTMKW-UHFFFAOYSA-N ethene;ethyl prop-2-enoate Chemical compound C=C.CCOC(=O)C=C CGPRUXZTHGTMKW-UHFFFAOYSA-N 0.000 description 1
- QHZOMAXECYYXGP-UHFFFAOYSA-N ethene;prop-2-enoic acid Chemical compound C=C.OC(=O)C=C QHZOMAXECYYXGP-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000005042 ethylene-ethyl acrylate Substances 0.000 description 1
- 239000005043 ethylene-methyl acrylate Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- SKRPCQXQBBHPKO-UHFFFAOYSA-N fluorocyclobutane Chemical compound FC1CCC1 SKRPCQXQBBHPKO-UHFFFAOYSA-N 0.000 description 1
- SXBNZAGHSZDLTC-UHFFFAOYSA-N fluorocycloheptane Chemical compound FC1CCCCCC1 SXBNZAGHSZDLTC-UHFFFAOYSA-N 0.000 description 1
- RQIOMXQOMYOGKD-UHFFFAOYSA-N fluorocyclohexane Chemical compound FC1[CH]CCCC1 RQIOMXQOMYOGKD-UHFFFAOYSA-N 0.000 description 1
- XGQGTPFASZJKCD-UHFFFAOYSA-N fluorocyclopentane Chemical compound FC1[CH]CCC1 XGQGTPFASZJKCD-UHFFFAOYSA-N 0.000 description 1
- DVWNEKRVAURHBQ-UHFFFAOYSA-N fluoromethylcyclobutane Chemical compound FCC1CCC1 DVWNEKRVAURHBQ-UHFFFAOYSA-N 0.000 description 1
- RBXBDCRAJKXJCQ-UHFFFAOYSA-N fluoromethylcycloheptane Chemical compound FCC1CCCCCC1 RBXBDCRAJKXJCQ-UHFFFAOYSA-N 0.000 description 1
- YYKWXZYVDGWGSF-UHFFFAOYSA-N fluoromethylcyclopentane Chemical compound FCC1CCCC1 YYKWXZYVDGWGSF-UHFFFAOYSA-N 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- KSKYTIWOGUMFTK-UHFFFAOYSA-N formaldehyde;pentanedial Chemical compound O=C.O=CCCCC=O KSKYTIWOGUMFTK-UHFFFAOYSA-N 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003899 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005842 heteroatoms Chemical group 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000000984 immunochemical Effects 0.000 description 1
- 230000002998 immunogenetic Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001024 immunotherapeutic Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 200000000003 influenza A Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- BJHIKXHVCXFQLS-PYWDMBMJSA-N keto-D-sorbose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PYWDMBMJSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 230000002132 lysosomal Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 108010031099 mannose receptor Proteins 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- HTEAGOMAXMOFFS-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.COC(=O)C(C)=C HTEAGOMAXMOFFS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 101700045377 mvp1 Proteins 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000001613 neoplastic Effects 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 101700050775 oct-1 Proteins 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 244000039328 opportunistic pathogens Species 0.000 description 1
- 230000036220 oral bioavailability Effects 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 101710031992 pRL90232 Proteins 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000003071 parasitic Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 229960004692 perflenapent Drugs 0.000 description 1
- LRMQIJUOLGKFKS-UHFFFAOYSA-N perfluoro-1,3-dimethyladamantane Chemical compound FC1(F)C(C2(F)F)(F)C(F)(F)C3(F)C(F)(F)C1(C(F)(F)F)C(F)(F)C2(C(F)(F)F)C3(F)F LRMQIJUOLGKFKS-UHFFFAOYSA-N 0.000 description 1
- WKHMXCIUCCIPOU-UHFFFAOYSA-N perfluoro-1-methyladamantane Chemical compound FC1(F)C(C2(F)F)(F)C(F)(F)C3(F)C(F)(F)C2(F)C(F)(F)C1(C(F)(F)F)C3(F)F WKHMXCIUCCIPOU-UHFFFAOYSA-N 0.000 description 1
- ZYYBBMCBAFICKK-UHFFFAOYSA-N perfluoro-N-cyclohexylpyrrolidine Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)N1C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F ZYYBBMCBAFICKK-UHFFFAOYSA-N 0.000 description 1
- MRQNKLRMROXHTI-UHFFFAOYSA-N perfluoro-N-methyldecahydroisoquinoline Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(F)(F)N(C(F)(F)F)C(F)(F)C(F)(F)C21F MRQNKLRMROXHTI-UHFFFAOYSA-N 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- BPHQIXJDBIHMLT-UHFFFAOYSA-N perfluorodecane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F BPHQIXJDBIHMLT-UHFFFAOYSA-N 0.000 description 1
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 description 1
- JAJLKEVKNDUJBG-UHFFFAOYSA-N perfluorotripropylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F JAJLKEVKNDUJBG-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000090 phagocyte Effects 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 101710035540 plaa2 Proteins 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 108010048507 poliovirus receptor Proteins 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- FBCQUCJYYPMKRO-UHFFFAOYSA-N prop-2-enyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC=C FBCQUCJYYPMKRO-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000035812 respiration Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036332 sexual response Effects 0.000 description 1
- 230000001340 slower Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- WQQPDTLGLVLNOH-UHFFFAOYSA-M sodium;4-hydroxy-4-oxo-3-sulfobutanoate Chemical class [Na+].OC(=O)CC(C([O-])=O)S(O)(=O)=O WQQPDTLGLVLNOH-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003393 splenic Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 239000005437 stratosphere Substances 0.000 description 1
- 229920000638 styrene acrylonitrile Polymers 0.000 description 1
- 239000011115 styrene butadiene Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- XVTUQDWPJJBEHJ-KZCWQMDCSA-N tetrastearoyl cardiolipin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)CO[P@@](O)(=O)OCC(O)CO[P@](O)(=O)OC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC XVTUQDWPJJBEHJ-KZCWQMDCSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000031998 transcytosis Effects 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000004855 vascular circulation Effects 0.000 description 1
- 210000000605 viral structures Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
Images
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10693298A | 1998-06-29 | 1998-06-29 | |
| US09/106,932 | 1998-06-29 | ||
| US13384898A | 1998-08-14 | 1998-08-14 | |
| US09/133,848 | 1998-08-14 | ||
| US9820603 | 1998-09-29 | ||
| PCT/US1998/020602 WO1999016419A1 (fr) | 1997-09-29 | 1998-09-29 | Microparticules perforees et procedes d'utilisation |
| PCT/US1998/020613 WO1999016421A1 (fr) | 1997-09-29 | 1998-09-29 | Preparations bioactives stabilisees et leur procedes d'utilisation |
| PCT/US1998/020603 WO1999016420A1 (fr) | 1997-09-29 | 1998-09-29 | Preparations stabilisees pour nebuliseurs |
| US9820615 | 1998-09-29 | ||
| PCT/US1998/020615 WO1999016422A1 (fr) | 1997-09-29 | 1998-09-29 | Preparations stabilisees pour aerosols-doseurs |
| US9820613 | 1998-09-29 | ||
| US9820602 | 1998-09-29 | ||
| US09/219,736 US6565885B1 (en) | 1997-09-29 | 1998-12-22 | Methods of spray drying pharmaceutical compositions |
| US09/219,736 | 1998-12-22 | ||
| US09/218,213 | 1998-12-22 | ||
| US09/218,209 | 1998-12-22 | ||
| US09/218,209 US6433040B1 (en) | 1997-09-29 | 1998-12-22 | Stabilized bioactive preparations and methods of use |
| US09/218,212 | 1998-12-22 | ||
| US09/218,212 US6309623B1 (en) | 1997-09-29 | 1998-12-22 | Stabilized preparations for use in metered dose inhalers |
| US09/218,213 US6946117B1 (en) | 1997-09-29 | 1998-12-22 | Stabilized preparations for use in nebulizers |
| PCT/US1999/006855 WO2000000215A1 (fr) | 1998-06-29 | 1999-03-31 | Systemes administration de particules et procedes d'utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003535017A JP2003535017A (ja) | 2003-11-25 |
| JP2003535017A5 true JP2003535017A5 (fr) | 2004-12-24 |
Family
ID=27557723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000556800A Pending JP2003535017A (ja) | 1998-06-29 | 1999-03-31 | 微粒子デリバリーシステムおよび使用の方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1091755A1 (fr) |
| JP (1) | JP2003535017A (fr) |
| KR (1) | KR100796220B1 (fr) |
| AU (1) | AU760537B2 (fr) |
| CA (1) | CA2335940A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9308199B2 (en) | 2004-04-29 | 2016-04-12 | Honeywell International Inc. | Medicament formulations |
| JP2007532619A (ja) * | 2004-04-13 | 2007-11-15 | ケンブリッジ バイオスタビリティ リミテッド | 懸濁したガラス粒子を含有する液体 |
| GB0408164D0 (en) * | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| WO2006101882A2 (fr) * | 2005-03-16 | 2006-09-28 | Honeywell International Inc. | Formulations galeniques de medicaments, dispositifs et procedes associes |
| JP2009524646A (ja) * | 2006-01-27 | 2009-07-02 | ザ・プロヴォスト，フェローズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホーリー・アンド・アンディヴァイデッド・トリニティー・オブ・クイーン・エリザベス，ニア・ダブリン | 多孔性微粒子の製造方法 |
| EP2589392B1 (fr) * | 2008-03-05 | 2016-11-30 | Sanofi Pasteur | Procédé de stabilisation d'une composition vaccinale contenant un adjuvant |
| KR20120132183A (ko) * | 2011-05-27 | 2012-12-05 | 포항공과대학교 산학협력단 | 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신 |
| CN102384973B (zh) * | 2011-08-10 | 2014-09-10 | 华南理工大学 | 快速定量检测羟甲基糠醛的免疫层析试纸条及其制备方法 |
| US9427376B2 (en) * | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2237510B (en) * | 1989-11-04 | 1993-09-15 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
| SK285068B6 (sk) * | 1997-09-29 | 2006-05-04 | Nektar Therapeutics | Práškový prostriedok, mikrosféry, spôsob tvorby časticového prostriedku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním a spôsob tvorby prášku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním |
-
1999
- 1999-03-31 EP EP99917320A patent/EP1091755A1/fr not_active Withdrawn
- 1999-03-31 KR KR1020007015026A patent/KR100796220B1/ko not_active IP Right Cessation
- 1999-03-31 JP JP2000556800A patent/JP2003535017A/ja active Pending
- 1999-03-31 CA CA002335940A patent/CA2335940A1/fr not_active Abandoned
- 1999-03-31 AU AU35469/99A patent/AU760537B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6630169B1 (en) | Particulate delivery systems and methods of use | |
| WO2000000215A1 (fr) | Systemes administration de particules et procedes d'utilisation | |
| JP6078498B2 (ja) | 計量吸入器における使用のための安定化調製物 | |
| US7842310B2 (en) | Pharmaceutical compositions in particulate form | |
| US20070065369A1 (en) | Novel methods and composition for delivering macromolecules to or via the respiratory tract | |
| US20020068090A1 (en) | Calcium phosphate particles as mucosal adjuvants | |
| AU760537B2 (en) | Particulate delivery systems and methods of use | |
| JP2003535017A5 (fr) | ||
| US20040213745A1 (en) | Powder formulations of rSEB for improved vaccination | |
| Mossadeq et al. | Formulation, Device, and Clinical Factors Influencing the Targeted Delivery of COVID-19 Vaccines to the Lungs | |
| US7141236B2 (en) | Methods and compositions for delivering macromolecules to or via the respiratory tract | |
| MXPA00012613A (en) | Particulate delivery systems and methods of use | |
| JP2004528339A (ja) | 気道に対して又は気道を介して高分子を送達するための新規方法及び組成物 | |
| Hellfritzsch et al. | Reconstituted Dry Powder Formulations of ZnO-Adjuvanted Ovalbumin Induce Equivalent Serum Antibody Responses to Ovalbumin Adjuvanted with Alhydrogel® or Cationic Adjuvant Formulation 01 (Caf® 01) | |
| MXPA00003103A (en) | Stabilized preparations for use in nebulizers |